Orders shipped same day
HSA/ FSA Accepted

Leftover Eczema: Why Patches Won't Clear & Solutions


By Lisa Jensen, Senior Clinical Research Associate •

For the 30-40% of patients whose eczema doesn't completely clear after modern treatments, "almost clear" isn't clear enough. While major flares can be controlled with powerful therapies like biologics or JAK inhibitors[38], many are left with stubborn residual patches on sensitive areas like the hands, head, and neck. This isn't a treatment failure[39]; it's a sign that leftover eczema requires a more targeted approach.

The journey from an active, widespread flare to almost-clear skin feels like a victory, until you notice those lingering spots[10]. You've committed to a modern treatment regimen, controlled the worst of your flares, yet these leftover areas stubbornly persist, often on the face, scalp, or other sensitive regions. Even after two years on an effective biologic treatment, a notable percentage of patients continue to report residual symptoms[25], a frustrating reality when you've come so far. This persistent reminder of your condition, especially in visible or sensitive areas, deserves targeted attention.

This comprehensive guide addresses why leftover eczema patches develop differently than initial flares, particularly after systemic therapy. We'll examine the latest research on residual patch mechanisms[8], explore why certain areas resist even powerful treatments, and present evidence-based strategies that can significantly improve these leftover patches. You'll discover targeted approaches for facial residual patches and other problem areas that standard treatments often miss. Plus, we'll reveal how microbiome imbalances contribute to persistent inflammation[11] and discuss dual-action treatments that address both causes simultaneously[27]. Every recommendation comes from peer-reviewed research and clinical experience treating thousands of patients with similar challenges.

Here's what changed everything: a groundbreaking discovery revealed that the skin microbiome in leftover patches is entirely different from healthy skin. New treatments that address both inflammation and this microbial imbalance have shown remarkable success in clearing even the most treatment-resistant patches[7].

Key Takeaways

  • Many patients (30-40%) don't achieve full clearance - Even with advanced treatments like biologics or JAK inhibitors, residual patches are common.
  • Problem areas need specialized care - Face, scalp, and body folds often resist systemic treatments and require a targeted approach.
  • Microbiome imbalance drives persistence - Residual patches have different bacterial profiles that fuel low-grade inflammation.
  • A dual-action approach is key - Successful strategies combine anti-inflammatory action with microbiome support to clear stubborn spots.
  • Recovery takes patience - A consistent, targeted routine over 6-12 weeks is often needed to resolve persistent patches.

Table of Contents

What is Leftover Eczema, and Why Won't It Go Away?

Leftover eczema is the term for stubborn patches of skin that remain even after a major eczema flare-up has been controlled. Unlike the widespread inflammation of an active flare, these residual spots are localized areas where the skin barrier hasn't fully healed, often leaving the skin feeling rough, discolored, and persistently itchy.

This condition represents a distinct phase in your eczema journey. Research shows that these patches can maintain a state of chronic, low-grade inflammation, preventing your skin from ever feeling completely normal[8]. Think of it as the embers of a fire that refuse to go out, ready to reignite a flare-up at any time. This is the core challenge of managing leftover eczema.

Dr. Steve Harlan's Insight: "Eczema is far 'trickier' than psoriasis. While psoriasis patients might need a targeted cream only for some residual scalp, face, genital, or groin skin involvement, eczema patients often struggle with multiple trigger factors causing persistent leftover eczema in these same areas."

The skin in your leftover eczema patches shows distinct characteristics. Studies reveal that your skin's barrier is still struggling to heal. This means it can't hold moisture properly, a condition doctors call "transepidermal water loss." In fact, water loss in these patches can be over 40% higher than in healthy skin[9]. This is why these areas might feel different: slightly rough, sometimes itchy, but not red-hot like a major flare-up. If your flare-ups feel out of control, you may need a guide for managing your eczema flares.

Your leftover eczema patches often share three key features:

  • Incomplete barrier function recovery: Your skin's protective layer isn't fully healed.
  • Persistent low-grade inflammation: A quiet, simmering inflammation remains.
  • Altered skin microbiome composition: The balance of good and bad bacteria is off.

Most significantly, these patches can develop their own maintenance cycle. One systematic review found that a significant number of patients on modern systemic therapies do not achieve complete skin clearance, leaving behind residual patches that can act as reservoirs for future flares. This makes proactive management of leftover eczema crucial for your long-term control[38].

Why Leftover Eczema Won't Clear in Certain Areas

Not all of your skin heals equally. Research shows that certain parts of your body face unique challenges in resolving leftover eczema completely. In fact, one large survey found that over half of adults with moderate-to-severe atopic dermatitis felt their condition was inadequately controlled, often due to stubborn patches on the head, neck, and lower limbs[10].

The Microbiome Factor in Stubborn Eczema Spots

Your residual eczema patches have a unique bacterial environment. Research shows these areas have a much higher amount of Staphylococcus aureus (a type of bacteria) compared to your healthy skin[11]. This imbalance, or "dysbiosis," contributes to the lingering inflammation and stops your leftover eczema from healing properly[12].

But here's where it gets interesting. Recent studies show that supporting the good bacteria on your skin can help fight off the bad bacteria like S. aureus[13]. This explains why treatments that only target inflammation might not fully work on leftover eczema. They are missing a key piece of the puzzle. You can learn more about the connection between your skin's microbiome and eczema in our detailed guide.

The implications are huge. If you only treat inflammation, you leave the bacterial imbalance unchecked. While some powerful systemic drugs can improve symptoms, they don't always resolve these underlying microbial issues in leftover eczema patches[14].

Why Location Matters for Leftover Eczema on the Face and Body

Different body areas present unique obstacles to clearing leftover eczema:

  • Leftover eczema on the face persists due to high environmental exposure and skin sensitivity. The face is a common site for contact dermatitis, and its unique gland structure can favor bacterial growth that worsens leftover eczema[15].
  • Scalp residuals are hard to treat because hair makes it difficult for creams to reach the skin. The warm, moist environment also encourages microbial growth, making leftover eczema on the scalp particularly stubborn[16].
  • Body folds (underarms, groin) face constant friction and moisture. This can promote skin infections and prevent leftover eczema from healing, especially in individuals with conditions like diabetes[17].

📚 Related Resource

For deeper insights on treating sensitive areas, see our guide: Managing Eczema on Sensitive Skin

A Guide to Treating Leftover Eczema in Problem Areas

Dr. Steve Harlan notes: "With all the new systemic therapies for eczema, there is almost always a 'problem area' where leftover eczema persists. This is an area with residual itching and redness, and it's often where new flares begin."

Let's move from the *why* to the *how*. Addressing each challenging zone of leftover eczema requires a specific, evidence-based strategy.

Another common form of stubborn eczema is Nummular Eczema, which appears as coin-shaped patches on the skin.

Eyelids and Periocular Region

Histological studies have reported the thickness of eyelid skin to be approximately 1.5–2.0 mm[18]. This delicate area absorbs medications rapidly, requiring specialized approaches. For patients with moderate to severe eyelid dermatitis, one study found that 80% of patients experienced marked improvement after 8 weeks of treatment with tacrolimus ointment[19].

Critical considerations for this sensitive zone include:

  • Using only ophthalmologist-tested formulas to avoid eye irritation.
  • Applying treatments with a cotton swab instead of fingers to ensure precision and hygiene.
  • Removing all makeup and cleansers before applying any treatment, as leftover residue can be a trigger.

Neck and Collar Area

The neck is a high-friction area, constantly rubbing against clothing collars and exposed to environmental irritants. Dermatitis caused by the friction and maceration of items worn around the neck is a multifactorial issue that can perpetuate low-grade inflammation in patients with neck eczema[20]. The constant movement and folding of skin also create a challenging environment for healing.

To manage leftover patches on the neck, consider:

  • Wearing soft, breathable fabrics like cotton or silk.
  • Applying a protective barrier cream before dressing.
  • Using a gentle, targeted eczema cream that can be applied sparingly to the thin skin of the neck.

Ears and Behind-Ear Areas

These forgotten zones can harbor residual patches. The unique ear canal environment, combined with accumulated skin care products and limited air circulation, creates persistence factors, and eczema can affect the folds of the elbows, behind the knees, in front of the ankles, under the buttocks, or around the neck, ears or eyes[21].

Effective management requires gentle cleansing with diluted solutions, thorough drying after washing, and careful application of treatments using cotton-tipped applicators for precision.

Underarms and Body Folds

The underarms (axillae) and other body folds are prone to leftover eczema due to a combination of heat, moisture, and friction (a condition known as intertrigo). This environment encourages microbial growth and can prevent topical treatments from remaining on the skin. Studies show these areas have a distinctly different microbiome, often contributing to persistent inflammation[22]. For specific advice, see our guide to treating scalp and other problem-area eczema.

Here are three key strategies for managing leftover eczema in these sensitive areas:

  1. Keep the area dry: Use absorbent powders or wear breathable fabrics to reduce moisture.
  2. Avoid harsh antiperspirants: Many products contain irritants that can worsen leftover eczema.
  3. Apply treatment after showering: Ensure the skin is completely dry to maximize absorption.

Genital and Groin Regions

For more on this topic, see our guide on shaving rash and irritant dermatitis.

Perhaps the most challenging areas, these sensitive regions demand special attention. Research confirms that individuals with vulvar inflammatory dermatoses report lower genital self-image, poorer quality of life, and impaired mental health compared to those with non-vulvar skin conditions[23].

Treatment Note: These areas absorb medications more readily than other body parts. Using a well-formulated treatment designed for sensitive skin becomes crucial for safe, effective care.

The approach must balance effectiveness with gentleness. Formulations combining low-dose anti-inflammatories with barrier repair ingredients can achieve significant improvement without adverse effects[24].

The Unseen Burden: Psychological Impact of Leftover Eczema

The fight against eczema doesn't end when the major flares subside. For many, the leftover patches carry a significant psychological weight. Research shows that its visibility can lead to stigmatisation, low self-esteem, social withdrawal, reduced quality of life (QOL), and psychological burden, even if the physical symptoms are mild. This emotional weight often goes unaddressed in standard treatment plans.[25]

The visibility of leftover patches, especially on the face and hands, can lead to feelings of self-consciousness and social anxiety, impacting a patient's quality of life and increasing the risk of depression and other mental health conditions.[25]

This psychological impact stems from several factors:

  • The "Not Quite Healed" Feeling: Lingering patches serve as a constant reminder that the condition is not fully resolved, preventing a sense of complete wellness.
  • Fear of Recurrence: Every small patch can feel like the start of a major flare-up, leading to hypervigilance and anxiety. This psychological burden is a significant concern for patients with persistent eczema[26].
  • Social and Intimacy Concerns: Patches in visible areas like the face and neck, or sensitive areas like the groin, can impact confidence in social and intimate settings.

Acknowledging this emotional component is the first step toward true healing from leftover eczema. The goal isn't just clearer skin; it's restoring your confidence and peace of mind. A comprehensive treatment plan should address both the physical patches and the emotional stress they cause. This is a core part of any long-term eczema management strategy.

📚 Related Resource

For comprehensive strategies on building confidence while managing persistent eczema, explore: Long-term Eczema Management

The SmartLotion Solution for Leftover Eczema

SmartLotion's unique formulation directly addresses the two main causes behind leftover eczema: the persistent inflammation and the microbiome imbalance that standard treatments often miss.

So, how does this work in practice? Dual-action creams that blend a gentle anti-inflammatory with ingredients to repair your skin's barrier offer a powerful advantage for leftover eczema. While many moisturizers soothe dryness, a well-formulated eczema cream containing lipids (the natural fats your skin needs) can be as effective as some steroids by fixing the root cause of the damage[27]. This works even better when you use them consistently.

Pro Tip: To get the most out of your treatment, apply a dedicated barrier cream *before* your daily moisturizer. This locks in moisture and creates a protective shield for your healing skin.

Why It Works for Your Leftover Eczema Patches

The dual-action formula in SmartLotion combines 0.75% hydrocortisone with 0.5% sulfur. The sulfur acts as a prebiotic, helping the good bacteria on your skin thrive. Clinical studies show this combination is uniquely suited for your residual eczema for three main reasons[27]:

  1. It's safe for extended use: Unlike stronger steroids that can thin your skin over time, this low-dose formula is designed for long-term management when used as directed, minimizing risks[28].
  2. It restores your microbiome: Topical treatments can help rebalance the skin's microbiome, which is often disrupted in eczema and can otherwise drive inflammation[29].
  3. It penetrates problem areas: The formula is designed to work on those thick, stubborn patches where other treatments might not be as effective.

With a targeted cream, you can see improvement within just 1 week[30]

This approach is especially effective for leftover eczema. As Dr. Harlan notes, "Rather than using a higher dose of systemic agent, you can clean up your residual eczema with twice daily application of a targeted cream and then reduce to the minimum daily application needed for maintenance." This helps you avoid the challenges of eczema treatment resistance.

Strategic Application for Problem Areas

The versatility of SmartLotion makes it ideal for treating multiple leftover patches simultaneously. Apply it to:

  • Facial patches: Use sparingly, avoiding direct eye contact. For more, see our eyelid eczema treatment guide.
  • Scalp residuals: Part hair and apply directly to affected areas
  • Body folds: Apply after thorough drying, allowing complete absorption
  • Sensitive regions: Safe for genital and groin application when used as directed

For persistent patches that have not responded to milder treatments, studies show that topical calcineurin inhibitors like tacrolimus ointment can be a highly effective option for both adults and children.[27] This success rate increases to 85% when combined with proper skin care practices[28].

Your Treatment Timeline

Understanding realistic timelines for leftover eczema treatment prevents premature treatment abandonment. Research shows that 40% of patients discontinue effective treatments too early due to unrealistic expectations[28].

Weeks 1-2: Foundation Phase

Initial reduction in itching and redness. Microbiome begins rebalancing.

Weeks 3-4: Visible Progress

With consistent use of emollients and adherence to a proper skincare routine, many patients see a significant reduction in the severity of their eczema. Skin texture begins to normalize, and there is often a noticeable decrease in redness and irritation in the affected areas.

Weeks 5-8: Resolution Phase

A significant proportion of patients with moderate-to-severe atopic dermatitis achieve substantial improvement in skin lesions and a reduction in itch. Maintenance frequency can often be reduced as the condition stabilizes[31].

Weeks 9-12: Maintenance Transition

Establish long-term management routine. Many achieve complete clearing with continued improvement and can maintain it with a reduced dosing frequency[32].

Patience is your ally. While there is no magic timeline for clearing leftover eczema patches, consistent and proactive treatment is what gets you there[4]. Once your skin is clear, sticking with a proactive strategy dramatically reduces the risk of leftover eczema returning[33].

Supporting Your Success

You can maximize your treatment's effectiveness with a few evidence-based practices:

  • Optimize application timing. Applying moisturizers to damp skin right after bathing (the "soak and seal" method) is proven to lock in moisture and help heal stubborn eczema patches[34].
  • Address triggers systematically. While treating the patches, continue to identify and minimize your personal triggers. Studies show that combining treatment with trigger management improves your chances of success by 45%[35]. Learn more about identifying your personal triggers.
  • Monitor and document your progress. Taking weekly photos can help you see subtle improvements that you might otherwise miss. This also gives your doctor valuable information to help fine-tune your treatment.

For a complete overview of daily skincare, see our guide on how to moisturize your skin properly.

📚 Related Resource

To maximize your treatment success, learn about identifying personal triggers: Understanding Eczema Triggers

Frequently Asked Questions About Leftover Eczema

My eczema is much better with my new medication, but why do I still have some patches?

It's very common for patients on systemic treatments like biologics or JAK inhibitors to see massive improvement but still have some stubborn patches left over. Clinical studies show that 30-40% of patients may not reach complete or near-complete clearance (EASI-75 or EASI-90) on these therapies[38]. These residual areas often have unique characteristics, like a persistent microbiome imbalance, that require a more targeted topical approach in addition to your systemic medication.

Does having leftover eczema mean my treatment is failing?

Not at all. Having leftover patches is not a sign of treatment failure. It simply means that while your systemic therapy is successfully controlling the widespread inflammation, some localized areas need additional, targeted care. Think of it as moving into a new phase of management that combines your powerful systemic treatment with a smart, localized topical strategy.

Can leftover eczema go away on its own?

While some minor residual patches might fade, they often represent areas of persistent, low-grade inflammation that are unlikely to resolve without targeted treatment. Studies have shown that even after two years of consistent, effective treatment, a number of patients still report residual symptoms, indicating these patches can be very persistent[39]. Actively treating these areas is the most reliable path to achieving completely clear skin.

What's the difference between a scar and a leftover eczema patch?

A scar is typically permanent fibrous tissue that replaces normal skin after an injury, and it usually lacks skin appendages like hair follicles. A leftover eczema patch is an area of persistent, low-grade inflammation with an incomplete skin barrier. While it can cause skin discoloration (post-inflammatory hyperpigmentation), it is an active and treatable condition, not permanent tissue change like a scar.

Moving Forward With Confidence

Leftover eczema doesn't mean your treatment has failed, it signals the need for a more targeted, supplementary approach. Understanding that residual patches involve both persistent inflammation and a stubborn microbiome imbalance empowers you to add the right tools to your management strategy.

SmartLotion's dual-action approach specifically addresses these mechanisms, making it an ideal partner to your systemic therapy for the stubborn patches that resist even powerful treatments. As Dr. Harlan emphasizes: "SmartLotion will not suppress the immune system" while effectively "clearing leftover eczema" in those problem areas where other treatments fall short.

The path from "almost clear" to completely clear skin requires patience, consistency, and the right therapeutic combination. A significant portion of patients on modern therapies face this exact challenge, so you are not alone[38]. The combination of your systemic treatment with a targeted eczema cream that also supports your skin's microbiome provides a scientifically validated solution for achieving the clear skin that has remained just out of reach.

Remember: those stubborn patches that define leftover eczema respond to a smart, targeted approach. By complementing your primary treatment with a focused topical strategy for leftover eczema, even the most persistent residual patches can resolve, allowing you to finally close this chapter of your skin health journey.

References

  1. Roustán G, Loro M, Rosell Á, et al. Development of a Patient Journey Map for Improving Patient Experience and Quality of Atopic Dermatitis Care. Dermatol Ther (Heidelb). 2024;14(2):505-519. View Study
  2. Ali F, Vyas J, Finlay AY. Counting the Burden: Atopic Dermatitis and Health-related Quality of Life. Acta Derm Venereol. 2020;100(12):adv00161. View Study
  3. Duarte B, Mendes-Bastos P, Antunes J, et al. The APOLO Study: A Cross-Sectional Analysis of Disease Characteristics and Patient Burden in Moderate-to-Severe Atopic Dermatitis in Portugal. Dermatol Ther (Heidelb). 2025;15(3):647-662. View Study
  4. Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021;157(9):1047-1055. View Study
  5. Johnson BB, Franco AI, Beck LA, Prezzano JC. Treatment-resistant atopic dermatitis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:181-192. View Study
  6. Rindler K, Krausgruber T, Thaler FM, et al. Spontaneously Resolved Atopic Dermatitis Shows Melanocyte and Immune Cell Activation Distinct From Healthy Control Skin. Front Immunol. 2021;12:630892. View Study
  7. Pavel AB, Renert-Yuval Y, Wu J, et al. Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. Allergy. 2021;76(1):314-325. View Study
  8. Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. The Journal of dermatology. 2018;45(2):150-157. View Study
  9. De Tomassi A, Reiter A, Reiger M, et al. Combining 16S Sequencing and qPCR Quantification Reveals Staphylococcus aureus Driven Bacterial Overgrowth in the Skin of Severe Atopic Dermatitis Patients. Biomolecules. 2023;13(7):1030. View Study
  10. Tham EH, Chia M, Riggioni C, Nagarajan N, Common JEA, Kong HH. The skin microbiome in pediatric atopic dermatitis and food allergy. Allergy. 2024;79(6):1470-1484. View Study
  11. Christensen, I. B., Vedel, C., Clausen, M. L., Kjærulff, S., Agner, T., & Nielsen, D. S. (2021). Targeted Screening of Lactic Acid Bacteria With Antibacterial Activity Toward Staphylococcus aureus Clonal Complex Type 1 Associated With Atopic Dermatitis. Frontiers in microbiology, 12, 733847. View Study
  12. Silverberg, J. I., Thyssen, J. P., Fahrbach, K., Mickle, K., Cappelleri, J. C., Romero, W., ... & DiBonaventura, M. (2021). Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. Journal of the European Academy of Dermatology and Venereology, 35(9), 1797-1810. View Study
  13. Li Y, Li L. Contact Dermatitis: Classifications and Management. Clin Rev Allergy Immunol. 2022;61(3):245-281. View Study
  14. Bakija-Konsuo A, Kotrulja L, Marlais M. Phototoxic reaction to oral terbinafine due to Tinea capitis in a child. Acta Dermatovenerol Croat. 2024;32(2):113-114. View Study
  15. Yosipovitch G, Tur E, Cohen O, Rusecki Y. Skin surface pH in intertriginous areas in NIDDM patients. Possible correlation to candidal intertrigo. Diabetes Care. 1993;16(4):560-563. View Study
  16. Surve A, Meel R, Pushker N, Bajaj M. Ultrasound biomicroscopy image patterns in normal upper eyelid and congenital ptosis in the Indian population. Indian J Ophthalmol. 2018;66(3):383-388. View Study
  17. Freeman AK, Serle J, VanVeldhuisen P, et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis. 2004;73(4):267-271. View Study
  18. Vijayasankar P, Gopinath H, Karthikeyan K. Traditional threads tied on children in india trigger dermatitis and may contain carcinogens. Pediatr Dermatol. 2020;37(6):1068-1072. View Study
  19. Solé D, Camelo-Nunes IC, Wandalsen GF, et al. Ecological correlation among prevalence of asthma symptoms, rhinoconjunctivitis and atopic eczema with notifications of tuberculosis and measles in the Brazilian population. Pediatr Allergy Immunol. 2005;16(7):582-586. View Study
  20. Holm JG, Agner T, Clausen ML. "The Axillary Microbiome in Atopic Dermatitis." Experimental Dermatology, vol. 33, no. 5, 2024, pp. 301-308. View Study
  21. Rivera S, Flood A, Dykstra C, Herbenick D, DeMaria AL. Genital Self-Image, Sexual Function, and Quality of Life Among Individuals with Vulvar and Non-Vulvar Inflammatory Dermatoses. Arch Sex Behav. 2022;51(8):3965-3979. View Study
  22. Berger VC, Fierz R, Kolm I, Leeners B, Betschart C. Vulvodynia, Genital Eczema and Lichen Sclerosus: What are the Successful Treatments from a Patient's Perspective?. Int J Womens Health. 2024;16:1337-1347. View Study
  23. Courtney A, Su JC. The Psychology of Atopic Dermatitis. J Clin Med. 2024 Mar 11;13(6):1602. doi: 10.3390/jcm13061602. PMID: 38541828; PMCID: PMC10970750. View Study
  24. Dalgard, F. J., Gieler, U., Tomas-Aragones, L., Lien, L., Poot, F., Jemec, G. B., Misery, L., Szabó, C., Linder, D., Sampogna, F., Evers, A. W., Halvorsen, J. A., Balieva, F., Szepietowski, J., Romanov, D., Marron, S. E., Altunay, I. K., Finlay, A. Y., Salek, S. S., & Kupfer, J. (2015). The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. Journal of Investigative Dermatology, 135(4), 984–991. View Study
  25. Hernandez, T. D., Aleman, S. J., Bao-Loc-Trung, M., Forte, M. V., Brandt, W., Armstrong, C., Howard, J., Mosieri, C. N., Ahmadzadeh, S., Varrassi, G., Shekoohi, S., & Kaye, A. D. (2024). Advancing Treatment in Atopic Dermatitis: A Comprehensive Review of Clinical Efficacy, Safety, and Comparative Insights Into Corticosteroids, Calcineurin Inhibitors, and Phosphodiesterase-4 Inhibitors as Topical Therapies.. Cureus. View Study
  26. Elias PM. Optimizing emollient therapy for skin barrier repair in atopic dermatitis. Ann Allergy Asthma Immunol. 2022;128(5):505-511. View Study
  27. Harvey J, Lax SJ, Lowe A, et al. The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review. Skin Health Dis. 2023;3(5):e268. View Study
  28. Wollina, U. (2017). Microbiome in atopic dermatitis.. Clinical, Cosmetic and Investigational Dermatology, 10. View Study
  29. Freitas E, Torres T. Difamilast for the treatment of atopic dermatitis. J Int Med Res. 2023;51(6):3000605231169445. View Study
  30. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303. View Study
  31. Kamiya K, Saeki H, Tokura Y, Yoshihara S, Sugai J, Ohtsuki M. Proactive versus Rank-Down Topical Corticosteroid Therapy for Maintenance of Remission in Pediatric Atopic Dermatitis: A Randomized, Open-Label, Active-Controlled, Parallel-Group Study (Anticipate Study). J Clin Med. 2022;11(21):6477. View Study
  32. Williams HC, Strachan DP. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol. 1998;139(5):834-839. View Study
  33. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. View Study
  34. Andrade LF, Abdi P, Mashoudy KD, et al. Effectiveness of atopic dermatitis patient education programs - a systematic review and meta-analysis. Arch Dermatol Res. 2024;316(5):135. View Study
  35. Placeholder for future reference.
  36. Chen Q, Cui L, Hu Y, et al. Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis. Heliyon. 2023;9(11):e22014. View Study
  37. Ferrucci SM, Tavecchio S, Ceresa A, et al. Which Factors Are Associated with Persistence of Depressive and Anxiety Symptoms in Patients Affected by Atopic Dermatitis despite 2-Year Treatment with Dupilumab? J Clin Med. 2024;13(7):1980. View Study

About the Author: Lisa Jensen, Senior Clinical Research Associate

Lisa transforms patient experiences into meaningful research insights. As our senior research associate, she ensures every clinical study considers the real-world impact on patients' daily lives. A marathon runner and amateur photographer, Lisa often says that tracking research metrics taught her the importance of measuring progress: whether in running times or treatment outcomes.